FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026179396> ?p ?o ?g. }

• W3026179396 abstract "Since early in 2020, the first people in Europe were infected with the SARS-CoV-2 virus leading to the COVID-2019 pandemic. In March 2020, we admitted the first patients with a SARS-CoV-2 infection in our hospital. Many of these patients eventually end up at the intensive care unit (ICU). We and others have previously reported that patients infected with SARS-CoV-2 admitted to the ICU have a strikingly high rate of thromboembolic complications ranging between 25% and 35%.1-3 These patients have a hypercoagulable state at admission on the ICU and show mainly renal impairment as second organ involvement. Thrombotic microangiopathy (TMA) is one of the consequences of sepsis and may be caused by greatly reduced levels of “a disintegrin-like metalloprotease with a thrombospondin type 1 motif, member 13” (ADAMTS13, von Willebrand cleaving protease). Severely reduced levels of ADAMTS13 (usually < 10%) cause accumulation of ultralarge von Willebrand factor (vWF) multimers, which can interact spontaneously with platelets, ultimately leading to microvascular thrombosis.4 The decrease of ADAMTS13 activity in consumptive coagulopathy has been shown to have a stronger relationship to platelet dynamics even before thrombocytopenia.5 There is also a probable risk of thrombosis induced by inflammation via vWF-platelet axis.6, 7 To clarify whether ADAMTS13 and vWF are indeed involved in the pathophysiology of the thromboembolic complications seen in patients with SARS-CoV-2 infection, we measured ADAMTS13 and vWF levels in 12 patients with a clinical suspicion of microangiopathy (Table 1). A formal ethics review for this study was deemed unnecessary by the local Ethics Committee. 6 Patients: LMWH (dalteparin), prophylactic dose (1 dd 5000 IU) 1 Patient: LMWH (dalteparin), high prophylactic dose (2 dd 5000 IU) 1 Patient: LMWH: therapeutic dose 3 Patients: UFH 1 Patient: Arterial Thrombolysis Laboratory results for these patients are shown in Table 2. All laboratory assays were measured in the central ISO-15189 accredited laboratory using an ACL Top 750 LAS coagulation analyzer (Werfen Diagnostics) using Coamatic factor VIII reagent (chromogenic factor VIII), QFA Thrombin reagent (fibrinogen), liquid antithrombin reagent (antithrombin), and D-dimer HS500 reagent (D-dimer) all obtained from Werfen diagnostics. Platelets were measured using an Alinity Hq hematology analyzer (Abbott Diagnostics). vWF antigen, vWF ristocetin cofactor activity (VWF:GPIbR), and ADAMTS13 activity were measured on an ACUstar chemiluminescence analyzer (Werfen); plasma creatinine concentration was measured on an Atellica chemistry analyzer (Siemens). The data in Table 2 show a low ADAMTS13 activity. In contrast, vWF levels and factor VIII levels are increased, probably due to activated endothelium.8 These data are in accordance with previously described results from patient with sepsis.9 The interaction between injured vessel wall, vWF, and ADAMTS 13 might be potentially relevant in the pathophysiological coagulation changes seen in sepsis patients with microthrombosis as seen in disseminated intravascular coagulation and microangiopathy.4, 10, 11 Low plasma levels of ADAMTS13 in sepsis patients are associated with worse outcome.12, 13 Because of the evidence indicating an association between vWF antigen: ADAMT13 ratio and risk on thrombosis, we also included this ratio to our measurements.14 As can be seen in Table 1, this ratio is high. Although the level of ADAMTS13 activity was not conclusive to confirm the microangiopathic state, the combination of low ADAMTS13 activity and high vWF levels might contribute to the microangiopathic state observed in these patients. We therefore suggest to include ADAMTS13 and vWF in the diagnostic workup of patient infected with SARS-CoV-2 when a microangiopathic state is suspected. AH and NK conceived the presented concept. AH wrote the manuscript with support from RB, MS, JW, and NK. The authors have no competing interests. All authors discussed the results and contributed to the final manuscript." @default.
• W3026179396 created "2020-05-29" @default.
• W3026179396 creator A5012927400 @default.
• W3026179396 creator A5032480026 @default.
• W3026179396 creator A5060537433 @default.
• W3026179396 creator A5077627178 @default.
• W3026179396 creator A5079712124 @default.
• W3026179396 date "2020-05-22" @default.
• W3026179396 modified "2023-09-29" @default.
• W3026179396 title "Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS‐CoV‐2" @default.
• W3026179396 cites W1969463403 @default.
• W3026179396 cites W2154205460 @default.
• W3026179396 cites W2339962867 @default.
• W3026179396 cites W2619206214 @default.
• W3026179396 cites W2805098025 @default.
• W3026179396 cites W2805630869 @default.
• W3026179396 cites W2810019455 @default.
• W3026179396 cites W2888789033 @default.
• W3026179396 cites W2897799986 @default.
• W3026179396 cites W3003825348 @default.
• W3026179396 cites W3015946392 @default.
• W3026179396 cites W3016764831 @default.
• W3026179396 doi "https://doi.org/10.1111/ijlh.13244" @default.
• W3026179396 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7280565" @default.
• W3026179396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32441844" @default.
• W3026179396 hasPublicationYear "2020" @default.
• W3026179396 type Work @default.
• W3026179396 sameAs 3026179396 @default.
• W3026179396 citedByCount "59" @default.
• W3026179396 countsByYear W30261793962020 @default.
• W3026179396 countsByYear W30261793962021 @default.
• W3026179396 countsByYear W30261793962022 @default.
• W3026179396 countsByYear W30261793962023 @default.
• W3026179396 crossrefType "journal-article" @default.
• W3026179396 hasAuthorship W3026179396A5012927400 @default.
• W3026179396 hasAuthorship W3026179396A5032480026 @default.
• W3026179396 hasAuthorship W3026179396A5060537433 @default.
• W3026179396 hasAuthorship W3026179396A5077627178 @default.
• W3026179396 hasAuthorship W3026179396A5079712124 @default.
• W3026179396 hasBestOaLocation W30261793961 @default.
• W3026179396 hasConcept C109523444 @default.
• W3026179396 hasConcept C126322002 @default.
• W3026179396 hasConcept C167814343 @default.
• W3026179396 hasConcept C203014093 @default.
• W3026179396 hasConcept C2776224515 @default.
• W3026179396 hasConcept C2776376669 @default.
• W3026179396 hasConcept C2777878052 @default.
• W3026179396 hasConcept C2778585876 @default.
• W3026179396 hasConcept C2779134260 @default.
• W3026179396 hasConcept C2779394231 @default.
• W3026179396 hasConcept C2779936836 @default.
• W3026179396 hasConcept C2780868729 @default.
• W3026179396 hasConcept C2780921031 @default.
• W3026179396 hasConcept C55728118 @default.
• W3026179396 hasConcept C71924100 @default.
• W3026179396 hasConcept C89560881 @default.
• W3026179396 hasConcept C90924648 @default.
• W3026179396 hasConceptScore W3026179396C109523444 @default.
• W3026179396 hasConceptScore W3026179396C126322002 @default.
• W3026179396 hasConceptScore W3026179396C167814343 @default.
• W3026179396 hasConceptScore W3026179396C203014093 @default.
• W3026179396 hasConceptScore W3026179396C2776224515 @default.
• W3026179396 hasConceptScore W3026179396C2776376669 @default.
• W3026179396 hasConceptScore W3026179396C2777878052 @default.
• W3026179396 hasConceptScore W3026179396C2778585876 @default.
• W3026179396 hasConceptScore W3026179396C2779134260 @default.
• W3026179396 hasConceptScore W3026179396C2779394231 @default.
• W3026179396 hasConceptScore W3026179396C2779936836 @default.
• W3026179396 hasConceptScore W3026179396C2780868729 @default.
• W3026179396 hasConceptScore W3026179396C2780921031 @default.
• W3026179396 hasConceptScore W3026179396C55728118 @default.
• W3026179396 hasConceptScore W3026179396C71924100 @default.
• W3026179396 hasConceptScore W3026179396C89560881 @default.
• W3026179396 hasConceptScore W3026179396C90924648 @default.
• W3026179396 hasIssue "5" @default.
• W3026179396 hasLocation W30261793961 @default.
• W3026179396 hasLocation W30261793962 @default.
• W3026179396 hasLocation W30261793963 @default.
• W3026179396 hasOpenAccess W3026179396 @default.
• W3026179396 hasPrimaryLocation W30261793961 @default.
• W3026179396 hasRelatedWork W2039241798 @default.
• W3026179396 hasRelatedWork W2076618516 @default.
• W3026179396 hasRelatedWork W2131949107 @default.
• W3026179396 hasRelatedWork W2276935527 @default.
• W3026179396 hasRelatedWork W2796128753 @default.
• W3026179396 hasRelatedWork W3026179396 @default.
• W3026179396 hasRelatedWork W3029498159 @default.
• W3026179396 hasRelatedWork W3152860551 @default.
• W3026179396 hasRelatedWork W3190943721 @default.
• W3026179396 hasRelatedWork W4293193375 @default.
• W3026179396 hasVolume "42" @default.
• W3026179396 isParatext "false" @default.
• W3026179396 isRetracted "false" @default.
• W3026179396 magId "3026179396" @default.
• W3026179396 workType "article" @default.